May 11, 2021

New Research Outlines a Critical Driver in an Immune Cell’s Defense against Melanoma

Researchers at Huntsman Cancer Institute have found critical new insights into how cells defend against melanoma. In a report published in Nature Communications, the team describes how an enzyme called nicotinamide phosphoribosyltransferase, or NAMPT, initiates antitumor activity. The researchers suggest that new therapies strengthening this pathway in immune cells could be the foundation for more effective treatments against melanoma.

Apr 12, 2021

Ovarian Cancer Patients Face Increased Risk of Mental Illness

Siqi Hu, PhD, is a member of the Hashibe Lab at Huntsman Cancer Institute. Hu presented results at the 2021 virtual American Association for Cancer Research Annual Meeting that women diagnosed with ovarian cancer were more than three times more likely to be diagnosed with mental illness such as anxiety, depression, and adjustment disorder than the general public.

Apr 08, 2021

Huntsman Cancer Institute Research Shows Melanoma Incidence and Mortality Higher in Utah Compared to Rest of U.S.

Utah had more melanoma deaths than any other state from 1975 to 2013, says a letter published today by HCI researchers in the New England Journal of Medicine. In contrast to the rest of the United States, melanoma mortality in Utah increased by 0.8% per year over that period. The researchers say this data emphasizes the need to stay vigilant about preventing melanoma.

Apr 01, 2021

Working to Eradicate Cancer Through Research Innovation

Every five to seven years, HCI goes through a rigorous application process to maintain status as a National Cancer Institute-Designated Comprehensive Cancer Center and prove we meet the highest national standards for cancer care and research. In 2020, the NCI granted renewed status and awarded HCI its best score yet. And despite the challenges of the coronavirus pandemic in 2020, HCI submitted more research grants than the year before and kept clinical trials open for 1,800 patients.

Apr 01, 2021

Bridging the Gap for Promising New Drugs

The Accelerator at the University of Utah, headed by Dr. David Bearss, is working in conjunction with the Huntsman Cancer Institute, the College of Pharmacy, and the Partners for Innovation, Ventures, Outreach and Technology Center to break down the barriers investigators and researchers face in bringing new drugs and technologies to the public.

Apr 01, 2021

Reimagining Research in a Remote World

In March 2020, COVID-19 led to restrictions in on-site activities at HCI, at the University of Utah, across the state, and throughout the nation. HCI researchers were determined to keep labs functioning while also keeping employees safe. Learn how they overcame challenges and kept cancer research moving ahead.

Apr 01, 2021

Bringing Hope Closer to Cancer Patients

Clinical trials bring hope to patients in the form of innovative treatments. During the COVID-19 pandemic, despite strict hospital safety protocols and staff switching to remote work, HCI clinical research teams found a way to make sure patients could safely enroll and stay on clinical trials—remaining steadfast in our commitment to bring promising research advances to patients.

Apr 01, 2021

Banding Together to Advance Scientific Progress

When cancer researchers from different disciplines work together, they gain new insights into how cancer begins and how it can be treated. HCI is committed to providing an atmosphere where ideas can be created, cultivated, and shared. Here are some examples of how HCI scientists are collaborating to accelerate progress in cancer research.